Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 11,803 | 11,058 | 14,681 | 18,210 | 16,928 |
| Gross Profit | 11,803 | 11,058 | 14,681 | 18,210 | 16,928 |
| Operating Expenses | 18,510 | 18,403 | 18,671 | 21,082 | 16,114 |
| Operating Income | -6,707 | -7,344 | -3,990 | -2,873 | 814 |
| Interest Expense | 72 | 66 | 79 | 74 | 75 |
| Other Income | 7,857 | -4,141 | 8 | 5 | 671 |
| Pre-tax Income | 1,078 | -11,552 | -4,061 | -2,942 | 1,410 |
| Income Tax | 92 | N/A | N/A | N/A | N/A |
| Net Income Continuous | 986 | -11,552 | -4,061 | -2,942 | 1,410 |
| Net Income | $986 | $-11,552 | $-4,061 | $-2,942 | $1,410 |
| EPS Basic Total Ops | 0.20 | -4.10 | -1.60 | -1.10 | 0.50 |
| EPS Basic Continuous Ops | 0.23 | -4.12 | -1.56 | -1.13 | 0.54 |
| EPS Diluted Total Ops | 0.20 | -4.10 | -1.60 | -1.10 | 0.50 |
| EPS Diluted Continuous Ops | 0.22 | -4.08 | -1.56 | -1.13 | 0.50 |
| EBITDA(a) | $-6,030 | $-6,683 | $-3,575 | $-2,572 | $1,091 |